Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: Functional regulation of LDLR levels

• Main Authors: Carole Fruchart Gaillard (Author), Ali Ben Djoudi Ouadda (Author), Lidia Ciccone (Author), Emmanuelle Girard (Author), Sepideh Mikaeeli (Author), Alexandra Evagelidis (Author), Maïlys Le Dévéhat (Author), Delia Susan-Resiga (Author), Evelyne Cassar Lajeunesse (Author), Hervé Nozach (Author), Oscar Henrique Pereira Ramos (Author), Aurélien Thureau (Author), Pierre Legrand (Author), Annik Prat (Author), Vincent Dive (Author), Nabil G. Seidah (Author)
• Format: Book
• Published: Elsevier, 2023-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: The liver-derived circulating PCSK9 enhances the degradation of the LDL receptor (LDLR) in endosomes/lysosomes. PCSK9 inhibition or silencing is presently used in clinics worldwide to reduce LDL-cholesterol, resulting in lower incidence of cardiovascular disease and possibly cancer/metast...